Specialists in modelling non-communicable diseases

Tackling population health challenges means asking big questions, such as:

What impact will the increasing burden of chronic kidney disease have on healthcare costs over the next 20 years?
How can you look 10 to 20 years ahead to understand the impact of a new drug on its users and your revenue stream?
How do you determine whether it is clinically and financially feasible to progress a drug from Phase II to Phase III clinical trials?
What would be the health and economic benefits of earlier screening for the diagnosis and treatment of conditions such as chronic kidney disease or liver disease?
How can you boost a nation’s health with targeted help at different life stages?

And how do you even know which are the right questions to ask?

That’s where we can help.

Helping you make the best decisions

Our simulation and analysis expertise turns tomorrow’s population health questions and challenges into today’s focussed, specific, actionable decisions.

We can help you understand and explore those questions and challenges far into the future. Our scenario modelling will show you how different kinds of health interventions, drug innovations and policy changes can impact them.

And that will help you choose the best way forward.

Why Us?

Deep expertise in modelling non-communicable diseases, combined with entrepreneurial vision.

Why Us?

How do we do it?

We’ve created a specific process to help you find, ask and answer the right questions.

Method

What have we done?

We’ve answered many different kinds of questions for many different organisations in over 70 countries.

Track Record

Why choose us?

We have an experienced and multi-disciplinary team of software engineers, population health and policy research experts, and mathematicians.

Team

HealthLumen Blog

NEWS: Shift in England’s drinking during COVID-19 could lead to 150,000 more cases of disease by 2035

The Institute of Alcohol Studies has today released a report “Estimating the long-term health impacts of changes in alcohol consumption in England during the COVID-19 pandemic” which includes modelling undertaken by HealthLumen. The pandemic saw heavier drinkers consuming more alcohol and this trend is continuing. If consumption does not return to 2019 levels or lower, the modelling shows […]

Read

NEWS: The Covid Hangover report launch

Our latest modelling project, undertaken for the Institute of Alcohol Studies, looks at how pandemic drinking patterns could impact alcohol-related disease and death.

Read

Everything in moderation: the health and economic benefits of reducing salt consumption in the UK

We all know that too much salt is bad for our health! Consuming too much salt can lead to high blood pressure which can lead to a variety of different health conditions including stroke and coronary heart disease. These diseases combined, claim the lives of millions of people globally, and costs the NHS, as well […]

Read

Reducing Failure Rates of Phase 3 Clinical Trials: how microsimulation modelling can assist

Of the three main phases of clinical trials, by far the most expensive part of the process is the Phase 3 trial, typically requiring from several hundred to several thousand participants and costing up to $20 million on average. Furthermore, the process is fraught with risks with up to 70% of Phase 2 trials and […]

Read